Skip to main content

Table 1 Baseline characteristics of patients in the ‘L-carnitine’ group versus control group

From: Adding L-carnitine to antagonist ovarian stimulation doesn’t improve the outcomes of IVF/ ICSI cycle in patients with polycystic ovarian syndrome: a double-blind randomized clinical trial

Variable

L-Carnitine group

n = 47

Placebo group

n = 50

p-value*

Age (year)

29.8 (4.0)

30.4 (4.3)

0.55

Body mass index (Kg/m2)

27.4 (5.2)

27.4 (3.7)

0.96

FSH (IU/L)

5.7 (1.9)

5.7 (1.7)

0.96

LH (IU/L)

6.2 (3.9)

7.2 (3.1)

0.16

TSH (mIU/L)

1.5 (0.9)

1.8 (0.9)

0.20

AMH (ng/mL)

7.2 (3.7)

8.1 (4.4)

0.26

DHEA (μg/dL)

202.8 (119.4)

176.2 (132.2)

0.35

Free testosterone (nmol /L)

2.50 (1.6)

1.8 (1.1)

0.13

FBS (mg/dL)

94.1 (12.0)

92.4 (8.9)

0.43

Insulin (uIU/mL)

11.5 (5.3)

10.1 (5.6)

0.24

Cholesterol (mg/dL)

161.1 (38.7)

162.1 (35.4)

0.89

Triglyceride (mg/dL)

141.4 (50.8)

120.7 (52.1)

0.06

LDL (mg/dL)

98.6 (32.6)

96.3 (27.1)

0.71

HDL (mg/dL)

43.5 (14.0)

46.7 (12.4)

0.26

Infertility duration (year)

6.8 (3.9)

6.5 (4.0)

0.77

Type of infertility

Primary

40 (85.1)

39 (78.0)

0.36

Secondary

7 (14.9)

11 (22.0)

Cause of infertility

PCOS

26 (55.3)

36 (72.0)

0.10

PCOS& male factor

21 (44.7)

14 (28.0)

Phenotypeα

A

23 (43.9)

18 (36.0)

0.16

B

6 (12.8)

3 (6.0)

C

12 (25.5)

20 (40.0)

D

6 (13.8)

9 (18.0)

No. of previous IUI

2.3 (1.4)

2.0 (0.95)

0.46

  1. Values are presented as the mean ± Standard deviation (SD) and number (percent). * Obtained by independent t test and chi square test. Statistically significant level was 0.05
  2. α Phenotype A (full-fledged polycystic ovary syndrome (PCOS): HA + OD + PCO) includes hyperandrogenism (HA) (clinical or biochemical), ovulatory dysfunction (OD), and polycystic ovaries (PCO) (HA + OD + PCO). Phenotype B (non-PCO PCOS: HA + OD). Phenotype C (ovulatory PCOS: HA + PCO). Phenotype D (non-hyperandrogenic PCOS: OD + PCO) [13]